Amgen reported $7.7 billion in net income for FY2025 — an 88.5% surge. But operating cash flow fell 13.3%, free cash flow collapsed 22%, and accounts receivable spiked 41% against just 10% revenue growth. Meanwhile, buried in the product revenue footnote: growth products overtook legacy at-risk drugs for the first time. The patent cliff narrative is partially obsolete — but a $12.3 billion debt maturity wall and negative ROIIC complicate everything.
AbbVie buried $15 billion in non-cash charges inside its fiscal 2025 10-K — more than triple its reported net income. The 96x GAAP P/E collapses to 21x on a cash basis, but $25.4 billion in contingent consideration obligations and a franchise concentration reboot (42.3% of revenue in two drugs, heading to 51.5%) reveal the truth sits between the extremes.
Merck reported 8% EPS growth and tripled its buybacks in FY2025. But the 10-K reveals free cash flow collapsed 32% to $12.4 billion, funded by $14 billion in new debt that halved its debt coverage ratio. With Keytruda — 49% of total sales — facing a triple cliff of patent expiry, IRA pricing, and MFN constraints in 2028-2029, we analyze whether the pipeline's $4.4 billion in replacement revenue can scale fast enough to bridge a $31.7 billion gap.
Pfizer reported $1.36 in GAAP earnings per share for FY2025 — while paying a negative effective tax rate for the third consecutive year. Strip the tax distortion and EPS falls to $1.04. But the Biopharma segment quietly earned $29.3 billion at a 47.9% margin, up 3.1 percentage points. The 10-K reveals two depletion clocks running simultaneously: $4.68B/year in intangible amortization mechanically lifting GAAP EPS, and $18.5B in patent cliff exposure destroying revenue — with the curves crossing in 2027-2028.
Bristol-Myers Squibb just reported the largest earnings swing in its history — net income reversed from a $8.9 billion loss to a $7.1 billion profit. Wall Street sees a recovery story. But the 10-K reveals free cash flow declined 7.9% to $12.8 billion, and three compression vectors — IRA pricing, an unprecedented government trade deal, and EU generics already launching — are converging on BMY's revenue faster than the market's 2028 patent cliff timeline implies. At 11.7% FCF yield, BMY is either the most undervalued cash generator in large-cap pharma or a controlled decline the market has priced correctly.
Eli Lilly's ROIC doubled from 23% to 52% in 2.5 years as Mounjaro and Zepbound drove 54% revenue growth. Meanwhile, AbbVie's Humira declined 56% to biosimilar competition, testing whether Skyrizi and Rinvoq can fill a $20B revenue gap. This pharma divergence reveals how drug pipelines translate to capital efficiency.